Subtype
Prostate Neoplasm
CI-CAN-00003778Explore in graph →
Non-malignant1,453 active trials24 approved drugs58 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00003778Explore in graph →
Clinical trials
6,544 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03199586 | Clinical Trial of Metastasis Inhibitor NP-G2-044 in Patients With Advanced or Metastatic Treatment-Refractory Solid Tumor Malignancies | completed | Phase 1 | 23 | Novita Pharmaceuticals, Inc.INDUSTRY | 1 | Jul 20, 2025 | clinicaltrials |
| NCT02204072 | BI836845 Plus Enzalutamide in Castrate Resistant Prostate Cancer (CRPC) | completed | Phase 1 | 120 | Boehringer IngelheimINDUSTRY | 8 | Jul 15, 2025 | clinicaltrials |
| NCT04580485 | INCB106385 Alone or in Combination With Immunotherapy in Advanced Solid Tumors | completed | Phase 1 | 54 | Incyte CorporationINDUSTRY | 6 | Jul 11, 2025 | clinicaltrials |
| NCT05253053 | To Evaluate Efficacy and Safety of TT-00420 (Tinengotinib) as Monotherapy and Combination Therapy in Patients With Advanced Solid Tumors | completed | Phase 1 / Phase 2 | 84 | TransThera Sciences (Nanjing), Inc.INDUSTRY | 1 | Jun 12, 2025 | clinicaltrials |
| NCT04068896 | Study of NGM120 in Subjects With Advanced Solid Tumors, Pancreatic Cancer, and Prostate Cancer Using Combination Therapy | completed | Phase 1 / Phase 2 | 89 | NGM Biopharmaceuticals, IncINDUSTRY | 1 | May 29, 2025 | clinicaltrials |
| NCT06389695 | Pharmacokinetics, Biodistribution, Radiation Dose and Safety Study of 68Ga-NYM032 in Patients | completed | Phase 1 / Phase 2 | 20 | Norroy Bioscience Co., LTDINDUSTRY | 1 | May 21, 2025 | clinicaltrials |
| NCT00328614 | Samarium-153 With Neoadjuvant Hormonal and Radiation Therapy for Locally Advanced Prostate Cancer | completed | Phase 1 | 32 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson UniversityOTHER | 1 | May 16, 2025 | clinicaltrials |
| NCT01420250 | Cabazitaxel With Radiation and Hormone Therapy for Prostate Cancer | completed | Phase 1 | 20 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson UniversityOTHER | 1 | May 15, 2025 | clinicaltrials |
| NCT01848067 | Alisertib, Abiraterone Acetate and Prednisone in Treating Patients With Hormone-Resistant Prostate Cancer | completed | Phase 1 / Phase 2 | 9 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson UniversityOTHER | 1 | May 4, 2025 | clinicaltrials |
| NCT02603965 | Copper Cu 64 TP3805 PET in Detecting Cancer in Patients With Prostate Cancer Undergoing Surgery | completed | Phase 1 | 25 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson UniversityOTHER | 1 | May 2, 2025 | clinicaltrials |
| NCT02339168 | Enzalutamide and Metformin Hydrochloride in Treating Patients With Hormone-Resistant Prostate Cancer | completed | Phase 1 | 25 | University of California, DavisOTHER | 1 | May 1, 2025 | clinicaltrials |
| NCT03076203 | Phase IB Trial of Radium-223 and Niraparib in Patients With Castrate Resistant Prostate Cancer (NiraRad) | completed | Phase 1 | 14 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson UniversityOTHER | 1 | Apr 29, 2025 | clinicaltrials |
| NCT04925284 | Study of XB002 in Subjects With Solid Tumors (JEWEL-101) | completed | Phase 1 | 269 | ExelixisINDUSTRY | 9 | Apr 4, 2025 | clinicaltrials |
| NCT06377683 | Clinical Evaluation of 177Lu-DansyI-PSMA (LNC1011) in Patients With Metastatic Castration-Resistant Prostate Cancer | completed | Phase 1 | 8 | The First Affiliated Hospital of Xiamen UniversityOTHER | 1 | Apr 1, 2025 | clinicaltrials |
| NCT02649790 | Study of the Safety, Tolerability and Efficacy of KPT-8602 in Participants With Relapsed/Refractory Cancer Indications | completed | Phase 1 / Phase 2 | 277 | Karyopharm Therapeutics IncINDUSTRY | 5 | Mar 19, 2025 | clinicaltrials |
| NCT06559007 | Phase 1 Study to Evaluate PK, Safety, and Tolerability of HRS-5041 in Healthy Caucasian Male Participants | completed | Phase 1 | 24 | Atridia Pty Ltd.INDUSTRY | 1 | Mar 18, 2025 | clinicaltrials |
| NCT05332340 | Safety, Tolerability and Pharmacokinetics (PK) Evaluation of BZ371A, Topically Administered | completed | Phase 1 | 12 | Biozeus Biopharmaceutical S.A.INDUSTRY | 1 | Mar 7, 2025 | clinicaltrials |
| NCT04428203 | Epidiolex (CBD) in Patients With Biochemically Recurrent Prostate Cancer | completed | Phase 1 | 21 | Zin W MyintOTHER | 1 | Mar 5, 2025 | clinicaltrials |
| NCT01792687 | Safety, Tolerability, Pharmacokinetics, and Preliminary Anti-tumor Activity of Ascending Doses of ARN 509 in Combination With Abiraterone Acetate | completed | Phase 1 | 6 | Aragon Pharmaceuticals, Inc.INDUSTRY | 1 | Mar 4, 2025 | clinicaltrials |
| NCT05441501 | A Study of JNJ-80038114 in Participants With Advanced Stage Prostate Cancer | completed | Phase 1 | 39 | Janssen Research & Development, LLCINDUSTRY | 2 | Mar 4, 2025 | clinicaltrials |
| NCT03073395 | Preliminary Evaluation of Uptake of [68Ga]P16-093 in Metastatic Prostate and Renal Cancer | completed | Phase 1 | 30 | Five Eleven Pharma, Inc.INDUSTRY | 1 | Feb 26, 2025 | clinicaltrials |
| NCT03805594 | 177Lu-PSMA-617 and Pembrolizumab in Treating Patients With Metastatic Castration-Resistant Prostate Cancer | completed | Phase 1 | 43 | University of California, San FranciscoOTHER | 1 | Feb 25, 2025 | clinicaltrials |
| NCT01638533 | Romidepsin in Treating Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Solid Tumors With Liver Dysfunction | completed | Phase 1 | 37 | National Cancer Institute (NCI)NIH | 2 | Feb 7, 2025 | clinicaltrials |
| NCT02625857 | Safety & Immunogenicity of JNJ-64041809, a Live Attenuated Double-deleted Listeria Immunotherapy, in Participants With Metastatic Castration-resistant Prostate Cancer | completed | Phase 1 | 26 | Janssen Research & Development, LLCINDUSTRY | 1 | Feb 3, 2025 | clinicaltrials |
| NCT04703920 | Talazoparib in Combination With Belinostat for Metastatic Breast Cancer, Metastatic Castration Resistant Prostate Cancer, and Metastatic Ovarian Cancer | completed | Phase 1 | 26 | University of Michigan Rogel Cancer CenterOTHER | 1 | Jan 23, 2025 | clinicaltrials |
| NCT02182219 | Oral Treatment With BIBF 1120 Together With Docetaxel and Prednisone in Patients With Hormone Refractory Prostate Cancer | completed | Phase 1 | 21 | Boehringer IngelheimINDUSTRY | 0 | Jan 22, 2025 | clinicaltrials |
| NCT04487847 | 18F-PSMA-1007 PET Imaging to Detect Primary Prostate Cancer(PICture) | completed | Phase 1 / Phase 2 | 75 | Radboud University Medical CenterOTHER | 1 | Jan 16, 2025 | clinicaltrials |
| NCT03518606 | Metronomic Oral Vinorelbine Plus Anti-PD-L1/Anti-CTLA4 ImmunothErapy in Patients With Advanced Solid Tumours(MOVIE) | completed | Phase 1 / Phase 2 | 126 | UNICANCEROTHER | 1 | Jan 15, 2025 | clinicaltrials |
| NCT06398470 | Study to Evaluate a New Method to Detect Residual Tumours During Surgery for Prostate Cancer Using Confocal Microscopy | completed | Phase 1 / Phase 2 | 21 | University College, LondonOTHER | 1 | Jan 10, 2025 | clinicaltrials |
| NCT01784913 | A Phase I/IIa Study of UV1 Vaccine in Patients With Prostate Cancer(UV1/hTERT2012P) | completed | Phase 1 / Phase 2 | 22 | Ultimovacs ASAINDUSTRY | 1 | Dec 16, 2024 | clinicaltrials |
| NCT01284920 | A Study of MDV3100 to Evaluate Safety, Tolerability, Pharmacokinetics and Efficacy of in Prostate Cancer Patients | completed | Phase 1 / Phase 2 | 47 | Astellas Pharma IncINDUSTRY | 1 | Nov 21, 2024 | clinicaltrials |
| NCT04094519 | A Study to Evaluate the Effect of Multiple Doses of Enzalutamide on the Pharmacokinetics of Substrates of P-glycoprotein (Digoxin) and Breast Cancer Resistant Protein (Rosuvastatin) in Male Subjects With Prostate Cancer | completed | Phase 1 | 24 | Astellas Pharma Global Development, Inc.INDUSTRY | 1 | Nov 20, 2024 | clinicaltrials |
| NCT03776968 | A Study Evaluating HC-1119 Single-Dose Pharmacokinetics and Effect of Food on Its Pharmacokinetics | completed | Phase 1 | 47 | Hinova Pharmaceuticals Inc.INDUSTRY | 1 | Oct 23, 2024 | clinicaltrials |
| NCT04978675 | An Investigational Scan (rh PSMA 7.3 PET/MRI) for the Detection of Recurrent Disease and Aid in Radiotherapy Planning in Biochemically Recurrent Prostate Cancer | completed | Phase 1 | 29 | M.D. Anderson Cancer CenterOTHER | 1 | Oct 23, 2024 | clinicaltrials |
| NCT06566989 | A Study of the Absorption, Distribution, Metabolism, and Elimination of Opevesostat (MK-5684) in Healthy Adult Male Participants (MK-5684-008) | completed | Phase 1 | 8 | Merck Sharp & Dohme LLCINDUSTRY | 1 | Oct 23, 2024 | clinicaltrials |
| NCT06554639 | A Drug-Drug Interaction Study of Diltiazem and MK-5684 in Healthy Adult Male Participants (MK-5684-011) | completed | Phase 1 | 12 | Merck Sharp & Dohme LLCINDUSTRY | 1 | Oct 15, 2024 | clinicaltrials |
| NCT02555397 | Phase 1 Trial of Interleukin 12 Gene Therapy for Locally Recurrent Prostate Cancer | completed | Phase 1 | 15 | Henry Ford Health SystemOTHER | 1 | Oct 10, 2024 | clinicaltrials |
| NCT04060394 | Dose-Escalation and Efficacy Study of LAE001/Prednisone Plus Afuresertib Patients With m-CRPC | completed | Phase 1 / Phase 2 | 49 | Laekna LimitedINDUSTRY | 2 | Oct 10, 2024 | clinicaltrials |
| NCT01774071 | Study of 89Zr-DFO-MSTP2109A in Patients With Prostate Cancer | completed | Phase 1 / Phase 2 | 19 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Oct 2, 2024 | clinicaltrials |
| NCT03558711 | PSMA-PET/CT for Prostate Cancer(NGP1) | completed | Phase 1 | 6 | University Hospital, GhentOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT05700669 | Study to Assess Safety and Efficacy of AsiDNA in Combination with Olaparib in Participants with Recurrent Solid Tumors | completed | Phase 1 / Phase 2 | 3 | Valerio TherapeuticsINDUSTRY | 1 | Sep 19, 2024 | clinicaltrials |
| NCT02566772 | Study of TAS3681 in Metastatic Castration Resistant Prostate Cancer | completed | Phase 1 | 130 | Taiho Oncology, Inc.INDUSTRY | 4 | Sep 3, 2024 | clinicaltrials |
| NCT01685268 | A Study of HSP90 Inhibitor AT13387 Alone or in Combination With Abiraterone Acetate | completed | Phase 1 / Phase 2 | 49 | Astex Pharmaceuticals, Inc.INDUSTRY | 4 | Aug 2, 2024 | clinicaltrials |
| NCT04701021 | TENDU Vaccine in Patients With Relapse After Primary Radical Prostatectomy | completed | Phase 1 | 12 | Ultimovacs ASAINDUSTRY | 1 | Jul 8, 2024 | clinicaltrials |
| NCT04284761 | A Study to Establish the Feasibility of Biolen for the Local Delivery of Bicalutamide in Patients With Prostate Cancer(Biolen-PC) | completed | Phase 1 | 17 | Alessa Therapeutics Inc.INDUSTRY | 3 | Jun 24, 2024 | clinicaltrials |
| NCT03276572 | Phase I Trial of 225Ac-J591 in Patients With mCRPC | completed | Phase 1 | 32 | Weill Medical College of Cornell UniversityOTHER | 1 | Jun 13, 2024 | clinicaltrials |
| NCT02933255 | PROSTVAC in Combination With Nivolumab in Men With Prostate Cancer | completed | Phase 1 / Phase 2 | 24 | National Cancer Institute (NCI)NIH | 1 | May 31, 2024 | clinicaltrials |
| NCT02184533 | Sodium Selenite and Radiation Therapy in Treating Patients With Metastatic Cancer | completed | Phase 1 | 15 | Stanford UniversityOTHER | 1 | May 28, 2024 | clinicaltrials |
Data updated 22 days agoSource updated Jul 20, 2025source: clinicaltrials